Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESILIENCE: Celecoxib in advanced head and neck cancer
NCT04162873Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Nov 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of celecoxib oral solution in head and neck cancer (HNC), sponsored by University of Utah. Started Nov 2019; status: terminated.
02
Drugs
celecoxib oral solution
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT04162873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162873.